B
Bullisch
Bullisch · 25%NVS
$136.39
Szenariopreis
$150.200
-0.421 (-0.28%)Zum Schluss
Loading chart…
- Hoch
- 150.900
- Eröffnung
- 150.220
- Volumengewichteter Durchschnittskurs
- 150.24
- Volumen
- 1.87M
- Marktkap.
- 217.41B
- Tief
- 149.625
- Umsatz
- 280.46M
- EV/EBITDA, TTM
- 12.31
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
KI-Analyse of Novartis AG (NVS)
HaltenNovartis AG is currently a hold. The stock is priced at $150.62, with a high RSI of 81.144 indicating it may be overbought. Despite a strong gross margin of 75.39% and a forward P/E of 14.71, recent pipeline setbacks, including the discontinuation of a key trial, raise concerns. The mixed analyst ratings suggest uncertainty, with only 8 out of 23 analysts recommending a buy. The main risk is the potential impact of clinical trial failures on future performance, which could affect investor confidence.
Analystenbewertungen (3)
-14.95% Abwärtspotenzial
Halten
1 Kaufen
2 Halten
0 Verkaufen
Aktuell: 150.20
Tief
112.00
Durchschnitt
127.75
Hoch
143.00
Morgan Stanley
Übergewichten
$156
2026-10-06
Morgan Stanley
2026-10-06
Kursziel
$156
Übergewichten
HSBC
Halten
$136
2026-09-10
HSBC
2026-09-10
Kursziel
$136
Halten
HSBC
Halten
$110
2026-09-09
HSBC
2026-09-09
Kursziel
$110
Halten
Citi
Kaufen
$135
2026-09-09
Citi
2026-09-09
Kursziel
$135
Kaufen
Deutsche Bank
Halten
—
2026-09-09
Deutsche Bank
2026-09-09
Kursziel
—
Halten
Bewertungskennzahlen
Das aktuelle erwartete KGV von Novartis AG (NVS) beträgt 14.71, verglichen mit dem 5-Jahres-Durchschnitt von 13.24.
Alphio-AI-Kursszenarien für NVS
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die NVS halten
Event-Zeitleiste
News
9.510-16stocktwitsNovartis Faces Multiple Clinical Setbacks Amid Pipeline Challenges
7.510-06CNBCStarbucks Opens Stores in Xinjiang Amid Controversy
8.510-03stocktwitsNovartis Partners with Abogen in $7.8 Billion Deal
8.510-02CNBCNovartis Signs $7.8 Billion Deal with Chinese Biotech Abogen
2.010-02NewsfilterNovartis Enters $7.8 Billion Licensing Deal with Chinese Biotech
NVS FAQ – beantwortet von Alphio AI
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Novartis AG is currently a hold. The stock is priced at $150.62, with a high RSI of 81.144 indicating it may be overbought. Despite a strong gross margin of 75.39% and a forward P/E of 14.71, recent pipeline setbacks, including the discontinuation of a key trial, raise concerns. The mixed analyst ratings suggest uncertainty, with only 8 out of 23 analysts recommending a buy. The main risk is the potential impact of clinical trial failures on future performance, which could affect investor confidence.
3 analysts cover NVS: 1 rate it Buy, 2 Hold and 0 Sell. The average price target is 127.75.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.